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Background:  Adding a fibrate to statin therapy has been suggested to reduce residual CHD risk associated with elevated triglycerides (TG) and 
low HDL-C. The effect of adding fenofibric acid (FA) to optimized atorvastatin therapy on carotid intima-media thickness (cIMT) progression was 
studied in patients with mixed dyslipidemia.  
methods: This phase 3, multicenter, double-blind, controlled study randomized 682 subjects with mixed dyslipidemia and a history of CHD or a risk 
equivalent. All subjects received atorvastatin + either FA or placebo for 24 months. The primary endpoint was the rate of change from baseline (BL) 
through month 24 of the mean posterior wall IMT of the common carotid arteries measured by ultrasound and analyzed by a repeated measures 
linear mixed effects model, with BL cIMT as one of the covariates. 
results: Subjects were 68% male, 88% Caucasian, and had a mean age of 61 years. After atorvastatin for >6 weeks, subjects had mean LDL-C 
of 84 mg/dL, HDL-C of 40 mg/dL, and median TG of 199 mg/dL. Mean cIMT at BL was 0.76 mm vs. 0.78 mm for combination and monotherapy, 
respectively (p=0.01). At month 24, combination therapy resulted in statistically significant improvements in TG (median = -31.3%) and HDL-C 
(mean = 8.3%) vs. monotherapy. The primary endpoint was -0.006 mm/yr in the combination group vs. 0.000 mm/yr in the monotherapy group 
(p=0.22). There were 24 pre-specified subgroup analyses; in 5 the treatment effect varied across levels (treatment-by-time-by-subgroup interaction 
p<0.05) favoring combination therapy in those with: age (>60 y), history of CAD, high IMT (>0.795 mm), TG (170-234 mg/dL), and statin use at 
entry, while favoring atorvastatin monotherapy in those not using a statin at entry. AEs were consistent with the known safety profiles of both drugs. 
AEs leading to discontinuation occurred in 14% of patients receiving combination therapy vs. 7% of patients on monotherapy (p=0.001).
conclusions: FA + atorvastatin combination therapy did not significantly improve cIMT progression vs. atorvastatin monotherapy. Combination 
therapy was favored in 4 higher risk subgroups, while atorvastatin monotherapy was favored in those not receiving a statin at entry.
